Brief: SI-BONE Q2 Revenue USD 48.63 Million Vs. IBES Estimate USD 48.1 Million

SI-BONE

04/08/2025 21:09

Overview

SI-BONE Inc Q2 2025 revenue grows 21.7%, beating analyst expectations, per LSEG data

Gross margin improves to 79.8%, up 80 basis points yr/yr

Co achieves positive adjusted EBITDA of $1 mln

Outlook

SI-BONE expects 2025 revenue between $195 mln and $198 mln

Company estimates full-year gross margin of 78.5% to 79.0%

SI-BONE anticipates operating expenses to grow ~10%

Company expects positive adjusted EBITDA for full-year 2025

Result Drivers

PROCEDURE DEMAND - U.S. revenue growth driven by strong underlying procedure demand

PHYSICIAN ENGAGEMENT - Growth in active U.S. physicians by ~25% contributed to revenue increase

PRODUCT LAUNCHES - Adoption of new product launches accelerated revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$48.63 mln
$48.10 mln (8 Analysts)
Q2 Net Income
-$6.15 mln
Q2 Gross Margin
79.8%
Q2 Basic EPS
-$0.14
Q2 Operating Expenses
$45.81 mln
Q2 Operating income
-$7 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for SI-BONE Inc is $25.00, about 30.4% above its August 1 closing price of $17.39

Press Release: ID:nGNX3CRYkD

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)